SLx-4090

DB05678InvestigationalSmall molecule

SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.

Mechanism: SLx-4090 inhibits Microsomal Triglyceride Transfer Protein (MTP). It acts selectively in the enterocytes lining the gastrointestinal tract, preventing the formation of chylomicrons which are used to transport triglyceride (TG) and cholesterol into the systemic circulation.
Curator reviewed
Primary indication: Investigated for use/treatment in hyperlipidemia.Curator reviewed
Formula / weight: C₃₁H₂₅F₃N₂O₄ · 546.546 g/mol (avg)
Code names: KD-026 · SLx-4090

Resolves to

Compound

Structure

InChIKeyAZUIUVJESCFSLJ-UHFFFAOYSA-NSMILESCOC1=CC=CC(C(=O)NC2=CC3=C(CN(CC3)C(=O)OC3=CC=CC=C3)C=C2)=C1C1=CC=C(C=C1)C(F)(F)F

Targets

What you can answer from here — as of June 12, 2020

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with SLx-4090, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.